PharmaCyte Biotech to Implement $10-Million Share Repurchase Program
businesswire.com
news
2022-06-02 00:00:00

June 02, 2022 09:00 AM Eastern Daylight Time LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-BoxÂ®, today announced that its Board of Directors (Board) has authorized a share repurchase program to repurchase up to $10 million of PharmaCyte's outstanding common stock. The share repurchase authorization is effective immediately for a two-year period.
